KELLEY VU: Open Payments
NPI 1588042162 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,028 in 32 payments from 15 companies in 2025. Trend: 2023 $863 · 2024 $635 · 2025 $1,028
Food & beverage: $933Education: $95
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 3 | $222 |
| Janssen Biotech, Inc. | 9 | $198 |
| Gilead Sciences, Inc. | 1 | $122 |
| AstraZeneca Pharmaceuticals LP | 4 | $103 |
| Novartis Pharmaceuticals Corporation | 3 | $71 |
| PFIZER INC. | 2 | $61 |
| PharmaEssentia USA Corporation | 2 | $44 |
| TerSera Therapeutics LLC | 1 | $36 |
| Merck Sharp & Dohme LLC | 1 | $34 |
| BeOne Medicines USA, Inc. | 1 | $33 |
Products named: Trodelvy, Vyloy, Xtandi, ERLEADA, TALVEY, SCEMBLIX, DARZALEX, TAGRISSO.
Industry payments across TX — which companies pay providers there.
